47 phenotypes from 5 alleles in 9 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Irf1M1Btlr/Irf1+ C57BL/6J-Irf1M1Btlr	decreased CD8-positive, alpha-beta T cell number	J:162995
	decreased NK cell number	J:162995
	normal hematopoietic system phenotype	J:162995
	normal immune system phenotype	J:162995
	impaired natural killer cell mediated cytotoxicity	J:162995
	increased susceptibility to Herpesvirales infection	J:162995
Irf1M1Btlr/Irf1M1Btlr C57BL/6J-Irf1M1Btlr	decreased CD8-positive, alpha-beta T cell number	J:162995
	decreased interferon-alpha secretion	J:162995
	decreased interferon-beta secretion	J:162995
	decreased NK cell number	J:162995
	normal hematopoietic system phenotype	J:162995
	normal immune system phenotype	J:162995
	impaired natural killer cell mediated cytotoxicity	J:162995
	increased susceptibility to Herpesvirales infection	J:162995
Irf1m2Btlr/Irf1m2Btlr C57BL/6J-Irf1m2Btlr	decreased CD8-positive, alpha-beta T cell number	J:267675
	decreased NK cell number	J:267675
	increased B-1 B cell number	J:267675
	increased CD4-positive, alpha-beta T cell number	J:267675
Irf1M3Btlr/Irf1M3Btlr C57BL/6J-Irf1M3Btlr	decreased CD8-positive, alpha-beta T cell number	J:267677
	increased CD4-positive, alpha-beta T cell number	J:267677
Irf1tm1Cwe/Irf1tm1Cwe involves: 129	abnormal circulating interleukin-4 level	J:84367
	abnormal circulating interleukin-10 level	J:84367
	abnormal cytokine level	J:84367
	abnormal T cell proliferation	J:84367
	decreased circulating interferon-gamma level	J:84367
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:84367
	increased circulating interleukin-5 level	J:84367
	increased circulating interleukin-6 level	J:84367
	increased circulating interleukin-13 level	J:84367
Irf1tm1Cwe/Irf1tm1Cwe involves: 129/Sv * C57BL/6	abnormal cytokine level	J:110672
	abnormal immune system morphology	J:21235
	abnormal immune system physiology	J:43086
	abnormal immunoglobulin level	J:101427
	abnormal macrophage physiology	J:43086
	abnormal splenocyte morphology	J:21235
	abnormal T cell morphology	J:21235, J:36025
	abnormal thymus cell ratio	J:36025
	decreased CD8-positive, alpha-beta T cell number	J:21235
	decreased circulating interleukin-2 level	J:110672
	decreased susceptibility to induced arthritis	J:43086
	increased circulating interferon-gamma level	J:110672
	increased circulating interleukin-3 level	J:110672
	increased circulating interleukin-4 level	J:110672
	increased circulating interleukin-5 level	J:110672
	increased circulating interleukin-6 level	J:110672
	increased susceptibility to Poxviridae infection	J:101427
	increased T-helper 2 cell number	J:110672
	normal skeleton phenotype	J:43086
Irf1tm1Mak/Irf1+ either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2)	no abnormal phenotype detected	J:64286
Irf1tm1Mak/Irf1tm1Mak B6.129S2-Irf1tm1Mak/J	abnormal circulating alanine transaminase level	J:111090
	abnormal lymphocyte physiology	J:91927
	decreased interferon-gamma secretion	J:91927
	increased incidence of tumors by chemical induction	J:91927
	increased lymphoma incidence	J:91927
	increased susceptibility to xenobiotic induced morbidity/mortality	J:91927
Irf1tm1Mak/Irf1tm1Mak either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2)	abnormal response to infection	J:64286
	abnormal T cell number	J:64286
	decreased CD8-positive, alpha-beta T cell number	J:64286
	normal immune system phenotype	J:64286
	increased CD4-positive, alpha-beta T cell number	J:64286
	increased double-positive T cell number	J:64286
Irf1tm1Mak/Irf1tm1Mak involves: 129S2/SvPas	abnormal DNA repair	J:115104
	normal cellular phenotype	J:115104
Irf1tm1Mak/Irf1tm1Mak involves: 129S2/SvPas * C57BL/6J	abnormal vascular wound healing	J:118512